Ependymoma
Methodology & AI Transparency ⓘ
Ependymoma Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Ependymoma—coded clinically as C71.9 across Cancer & Oncology guidelines—combines targeted/immunotherapy [Ependymoma C71.9] with structured follow-up of Pathology / Molecular in Ependymoma (C71.9: Genomic Staging) (Guideline-concordant surveillance (C71.9)).
- 2 Real-world patient consensus: Diagnostic registry C71.9: Ependymoma is managed within Cancer & Oncology.
- 3 Typical cash cost range: Differential triage of Ependymoma (C71.9) utilizes targeted/immunotherapy [Ependymoma C71.9].
- 4 Top reported side effects / signs: Follow-up benchmark in Ependymoma: maintaining Comprehensive Metabolic & in Ependymoma (C71.9: Organ Function Panel) within Preserved renal/hepatic clearance (C71.9).
Ask our AI Specialists anything about Ependymoma
What Is Ependymoma?
Ependymoma—coded clinically as C71.9 across Cancer & Oncology guidelines—combines targeted/immunotherapy [Ependymoma C71.9] with structured follow-up of Pathology / Molecular in Ependymoma (C71.9: Genomic Staging) (Guideline-concordant surveillance (C71.9)).
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Ependymoma (C71.9) features potential lymphatic or in Ependymoma (C71.9: hematogenous dissemination if). therapeutic stabilization in cancer & oncology is verified against Pathology / Molecular in Ependymoma (C71.9: Genomic Staging).
Common Symptoms & Clinical Signs
- • Presentation of Ependymoma (C71.9): persistent painless lump, in Ependymoma (C71.9: non-healing ulcer/mole change,)
- • Secondary Ependymoma clinical sign: unintended weight loss [Ependymoma C71.9]
- • Symptom flares in Ependymoma correlating with Comprehensive Metabolic & in Ependymoma (C71.9: Organ Function Panel) deviation outside Preserved renal/hepatic clearance (C71.9)
- • Functional cancer & oncology impact requiring targeted/immunotherapy [Ependymoma C71.9] evaluation (C71.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Ependymoma Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C71.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Ependymoma (C71.9: Organ Function Panel) | Preserved renal/hepatic clearance (C71.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Ependymoma (C71.9: Genomic Staging) | Guideline-concordant surveillance (C71.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Ependymoma (C71.9: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C71.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Ependymoma
Treatment selection for Ependymoma depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Ependymoma)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Nimotuzumab plus concurrent chemo-radiotherapy in unresectable locally advanced: What a 201-Participant Study Found Nimotuzumab, in combination with chemo-radiotherapy, increased the CRR and ORR with a good safety profile. British journal of cancer • 2023-11-15 • Phase III Randomized Trial | N = 201 | 88/100 | PMID 37864049 ↗ |
| New Insights on Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically: What a 350-Participant Study Found Our long-term follow-up confirms that a higher dose only increases the chances of gastrointestinal side effects without providing any benefits to the patient. European urology • 2026-03-15 • Phase III Randomized Trial | N = 350 | 87/100 | PMID 41494929 ↗ |
| New Insights on Proton Pump Inhibitor Use and the Efficacy of Chemotherapy in Metastatic: What a 620-Participant Study Found The significant interaction between PPI use and the type of fluoropyrimidine in terms of overall and progression-free survival suggests that fluorouracil could be a more favorable option than capecitabine for patients with... The oncologist • 2021-06-15 • Phase III Randomized Trial | N = 620 | 87/100 | PMID 33644953 ↗ |
| Can This Approach Help? Inside the Latest Research on Validation of VEGF and eNOS polymorphisms as predictors of first-line bevacizumab Moreover, the haplotype analyses did not confirm what was found in our previous study; patients bearing a specific haplotype of eNOS had not significantly improved outcomes. Scientific reports • 2023-08-09 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 37558720 ↗ |
| Can This Approach Help? Inside the Latest Research on Low-dose fractionated radiation with induction docetaxel and cisplatin followed The results showed no benefit from adding LDFRT to induction chemotherapy in terms of RR, OS, LRC, and DMFS. Hematology/oncology and stem cell therapy • 2021-09-15 • Phase III Randomized Trial | N = 108 | 82/100 | PMID 32504593 ↗ |
Ependymoma Patient Community & “People Like Me” Threads
Filter Ependymoma community threads and patient logs by age, biological sex, dosage, and treatment duration.